Charts • Infasurf (calfactant) Surfactant

Hit enter to search or ESC to close

Made to Do More
Resources
Prescribing Info
Contact

wdt_ID	wdt_created_by	wdt_created_at	wdt_last_edited_by	wdt_last_edited_at		Infasurf	Curosurf® (poractant alfa) 1,5	Survanta® (beractant) 1,6
1	[email protected]	Jan 10, 2025 02:40 PM	[email protected]	Jan 10, 2025 02:40 PM	Type	Natural - Bovine	Natural - Porcine	Semi-Synthetic - Bovine
2	[email protected]	Jan 10, 2025 02:40 PM	[email protected]	Jan 10, 2025 02:40 PM	SP-B Content (% of total Phospholipids)	0.74%	0.59%	0.04%
3	[email protected]	Jan 10, 2025 02:40 PM	[email protected]	Jan 10, 2025 02:40 PM	Initial Dose	3 mL/kg	2.5 mL/kg	4 mL/kg

Indication

Infasurf ^Ⓡ (calfactant) is indicated to reduce the risk of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment of premature infants who develop RDS. Infasurf decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS.

Prophylaxis
Prophylaxis therapy at birth with Infasurf is indicated for premature infants <29 weeks of gestational age at significant risk for RDS. Infasurf prophylaxis should be administered as soon as possible, preferably within 30 minutes after birth.

Treatment
Infasurf therapy is indicated for infants ≤72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.

Important Safety Information

Infasurf is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING INFASURF, OFTEN RAPIDLY IMPROVES OXYGENATION AND LUNG COMPLIANCE. Following administration of Infasurf, patients should be carefully monitored so that oxygen therapy and ventilatory support can be modified in response to changes in respiratory status.

Infasurf therapy is not a substitute for neonatal intensive care. Optimal care of premature infants at risk for RDS and newborn infants with RDS who need endotracheal intubation requires an acute care unit organized, staffed, equipped, and experienced with intubation, ventilator management, and general care of these patients.

TRANSIENT EPISODES OF REFLUX OF INFASURF INTO THE ENDOTRACHEAL TUBE, CYANOSIS, BRADYCARDIA, OR AIRWAY OBSTRUCTION HAVE OCCURRED DURING THE DOSING PROCEDURES that required stopping Infasurf and taking appropriate measures to alleviate the condition. After the patient is stable, dosing can proceed with appropriate monitoring.
An increased proportion of patients with both intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) was observed in Infasurf-treated infants in the Infasurf-Exosurf Neonatal controlled trials. These observations were not associated with increased mortality.

The most common adverse reactions associated with Infasurf dosing procedures in the controlled trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%). These events were generally transient and not associated with serious complications or death.

The incidence of common complications of prematurity and RDS in the four controlled Infasurf trials are presented in the Table. Prophylaxis and treatment study results for each surfactant are combined.

See full prescribing information

Comparative Trials
Dosing & Administration
FAQs
Why Infasurf

Composition
SP-B
Lower Dynamic Viscosity
Cost Effective

Prescribing Information
Request Information

Manufactured by ONY Biotech

455 Commerce Drive
Amherst, NY 14228
716.636.9096 | 877.274.4669

APM-0041 Rev. 10/2019

Infasurf® is a registered trademark of ONY Biotech Inc.

CUROSURF® is a registered trademark of Chiesi Farmaceutici S.p.A.

Survanta® is a registered trademark of Abbvie Inc.

Close Menu

Made to Do More
Resources
Prescribing Info
Contact